EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Entera Bio's Enterprise Value is €70.64 Mil.
Entera Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-6.99 Mil. Therefore, Entera Bio's EV-to-FCF for today is -10.11.
The historical rank and industry rank for Entera Bio's EV-to-FCF or its related term are showing as below:
FRA:5DT'
s EV-to-FCF Range Over the Past 10 Years
Min: -14.33 Med: -2.64 Max: -0.02
Current: -9.71
During the past 9 years, the highest EV-to-FCF of Entera Bio was -0.02. The lowest was -14.33. And the median was -2.64.
FRA:5DT's EV-to-FCF is ranked worse than 100% of 379
companies
in the Biotechnology industry
Industry Median: 8.34
vs FRA:5DT: -9.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-22), Entera Bio's stock price is €2.08.
Entera Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.259. Therefore, Entera Bio's PE Ratio for today is At Loss.
Entera Bio EV-to-FCF Historical Data
The historical data trend for Entera Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entera Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Entera Bio's EV-to-FCF falls into.
Entera Bio EV-to-FCF Calculation
Entera Bio's EV-to-FCF for today is calculated as:
Entera Bio's current Enterprise Value is €70.64 Mil.
Entera Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (FRA:5DT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Entera Bio's share price for today is €2.08.
Entera Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.259.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Entera Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Entera Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:5DT has been successfully added to your 